195 related articles for article (PubMed ID: 11851246)
21. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
22. Retrospective 5-year review of 131 patients with mycosis fungoides and Sézary syndrome seen at the National Skin Centre, Singapore.
Tan ES; Tang MB; Tan SH
Australas J Dermatol; 2006 Nov; 47(4):248-52. PubMed ID: 17034466
[TBL] [Abstract][Full Text] [Related]
23. Sézary syndrome presenting with 'leonine facies'.
Nassem S; Kashyap R; Awasthi NP; Krishnani N; Kumari N
Australas J Dermatol; 2009 Nov; 50(4):285-8. PubMed ID: 19916974
[TBL] [Abstract][Full Text] [Related]
24. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
25. Bilateral breast involvement in Sézary syndrome.
Balci P; Undar B; Yilmaz E; Seçil M; Ozsan H; Canda T
Eur Radiol; 2001; 11(12):2468-71. PubMed ID: 11734942
[TBL] [Abstract][Full Text] [Related]
26. Mycosis fungoides and Sezary syndrome against a human immunodeficiency virus-positive background: case report.
Gahongayire F
Int J Dermatol; 2007 Oct; 46 Suppl 1():32-5. PubMed ID: 17919204
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
28. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
Sato M; Ishikawa O; Miyachi Y
Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous T-cell lymphoma.
Lansigan F; Choi J; Foss FM
Hematol Oncol Clin North Am; 2008 Oct; 22(5):979-96, x. PubMed ID: 18954747
[TBL] [Abstract][Full Text] [Related]
30. [Peripheral blood Sézary cells and the diagnosis of Sézary syndrome].
Tessier-Marteau A; Le Corre Y; Gérard J; Avenel-Audran M; Geneviève F; Verret JL; Zandecki M
Ann Biol Clin (Paris); 2008; 66(4):447-53. PubMed ID: 18725348
[TBL] [Abstract][Full Text] [Related]
31. [A woman with Sezary syndrome developed HTLV-1-associated myeloneuropathy. The reported case supports the theory of etiological connection].
Roupe G
Lakartidningen; 2003 Jul; 100(30-31):2441-2. PubMed ID: 12914139
[TBL] [Abstract][Full Text] [Related]
32. Flow cytometric DNA ploidy analysis of peripheral blood from patients with sezary syndrome: detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue.
Wang S; Li N; Heald P; Fisk JM; Fadare O; Howe JG; McNiff JM; Smith BR
Am J Clin Pathol; 2004 Nov; 122(5):774-82. PubMed ID: 15491974
[TBL] [Abstract][Full Text] [Related]
33. [Primary cutaneous malignant lymphoma -- Sézary syndrome].
Vuković I; Stojimirović E; Milutinović S
Bilt Hematol Transfuz; 1978; 6(3):57-62. PubMed ID: 757669
[TBL] [Abstract][Full Text] [Related]
34. High-grade malignant lymphoma arising from Sézary's syndrome. A case report.
Kienitz T; Burg G; Schmoeckel C; Weitz H; Braun-Falco O
Dermatologica; 1979; 158(2):126-36. PubMed ID: 761696
[TBL] [Abstract][Full Text] [Related]
35. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.
Introcaso CE; Micaily B; Richardson SK; Junkins-Hopkins JM; Yoon JS; Kim EJ; Vittorio CC; Rook AH
J Am Acad Dermatol; 2008 Apr; 58(4):592-5. PubMed ID: 18249469
[TBL] [Abstract][Full Text] [Related]
36. Sézary syndrome in a cat.
Wood C; Almes K; Bagladi-Swanson M; Debey B; Andrews G; Nietfeld J; Wilkerson M
J Am Anim Hosp Assoc; 2008; 44(3):144-8. PubMed ID: 18451073
[TBL] [Abstract][Full Text] [Related]
37. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.
Roberts AA; Amano M; Felten C; Galvan M; Sulur G; Pinter-Brown L; Dobbeling U; Burg G; Said J; Baum LG
Mod Pathol; 2003 Jun; 16(6):543-51. PubMed ID: 12808059
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome.
Klemke CD; Mansmann U; Poenitz N; Dippel E; Goerdt S
Br J Dermatol; 2005 Jul; 153(1):118-24. PubMed ID: 16029336
[TBL] [Abstract][Full Text] [Related]
39. Serum Soluble CD48 Levels as a Prognostic Marker in Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T; Takahashi N; Nakajima R; Kamijo H; Suga H; Asano Y; Sugaya M; Sato S
J Invest Dermatol; 2018 Oct; 138(10):2286-2288. PubMed ID: 29605670
[No Abstract] [Full Text] [Related]
40. Light-microscopic analysis of sectioned Sézary cells: an accurate alternative to electron microscopy.
Myrie C; Zucker-Franklin D; Ramsey D
Am J Pathol; 1980 Apr; 99(1):243-52. PubMed ID: 7361860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
